Colorectal liver metastasis after 90Y radioembolization therapy: Pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response

American Journal of Roentgenology

Volumn 198, Issue 5, 2012, Pages 1093-1099

  Tochetto, Sandra M ^a   Töre, Hüseyin Gürkan ^a   Chalian, Hamid ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Attenuation; Colorectal liver metastasis; FDG PET; MDCT; Radioembolization; RECIST; Tumor response

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; COLORECTAL CANCER; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IOHEXOL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84860323997     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.6622     Document Type: Article

References (48)

1. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009; 50(suppl 1):1S-10S
2. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva; Switzerland, World Health Organization, 1979; whqlibdoc.who.int/publications/9241700483.pdf. Accessed December 10, 2010
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
5. 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008; 28:81-99
6. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 2009; 15:1891-1897
7. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019
8. Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26:183-189
9. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356:373-378 (Pubitemid 30487493)
10. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. Clin Cancer Res 2009; 15:1873-1882
11. Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from sameday repeat CT scans of patients with non-small cell lung cancer. Radiology 2009; 252:263-272
12. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60:1552-1563 (Pubitemid 39601873)
13. Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR 2007; 188:776-783
14. 90Y microspheres - safety, efficacy, and survival. Radiology 2008; 247: 507-515
15. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009; 50(suppl 1):43S-54S
16. Biasco G, Derenzini E, Grazi GL, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006; 32:214-228
17. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010; 78:237-248
18. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759 (Pubitemid 46797957)
19. 90Y help predict metabolic activity at FDG PET? Radiology 2010; 255:164-172
20. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145:340-345; discussion 345
21. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005; 43:189-204 (Pubitemid 40326568)
22. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-3945 (Pubitemid 46630742)
23. 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1. Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17:1251-1278
24. Kuhnigk JM, Dicken V, Bornemann L, et al. Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. IEEE Trans Med Imaging 2006; 25:417-434
25. Keil S, Behrendt FF, Stanzel S, et al. Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices: comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008; 18:2456-2465
26. Bornemann L, Dicken V, Kuhnigk JM, et al. OncoTREAT: a software assistant for cancer therapy monitoring. Int J Comput Assist Radiol Surg 2007; 1:231-242
27. Moltz JH, Bornemann L, Kuhnigk JM, et al. Advanced segmentation techniques for lung nodules, liver metastases, and enlarged lymph nodes in CT scans. IEEE J Sel Top Signal Process 2009; 3: 122-134
28. Frederick MG, Paulson EK, Nelson RC. Helical CT for detecting focal liver lesions in patients with breast carcinoma: comparison of noncontrast phase, hepatic arterial phase, and portal venous phase. J Comput Assist Tomogr 1997; 21:229-235 (Pubitemid 27120024)
29. Soyer P, Poccard M, Boudiaf M, et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 2004; 231:413-420 (Pubitemid 38552898)
30. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004; 31:1471-1478
31. Vriens D, de Geus-Oei LF, van Laarhoven HW, et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nucl Med Commun 2009; 30:550-557
32. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47:1059-1066
33. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-1782
34. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009; 115:1849-1858
35. Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol 2010; 21:1521-1526
36. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694
37. Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011; 22:780-786
38. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338-2344
39. Khan S, Tan YM, John A, et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol 2006; 32:564-567 (Pubitemid 44226008)
40. Funaioli C, Pinto C, Di Fabio F, et al. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori 2007; 93:611-615 (Pubitemid 351158075)
41. 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006; 76:696-703
42. White RR, Schwartz LH, Munoz JA, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol 2008; 97:601-604 (Pubitemid 351794150)
43. Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90 Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 2011; 38:1289-1295
44. Boppudi S, Wickremesekera SK, Nowitz M, Stubbs R. Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. Australas Radiol 2006; 50:570-577 (Pubitemid 44748082)
45. Carter S, Martin Ii RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) 2009; 11:541-550
46. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115:616-623
47. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720 (Pubitemid 34105661)
48. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20:4453-4458 (Pubitemid 35334757)